Answers are grounded in this paper and cite their sources.
Case report shows well tolerated palliative chemotherapy in a patient with bloom syndrome and metastatic colorectal cancer, suggesting a viable treatment path.
Background: Bloom syndrome is an autosomal recessive condition of genomic instability caused by increased sister-chromatid exchange, which results in a predisposition to a variety of cancers at a young age. The molecular alterations in Bloom Syndrome predisposing to chromosomal instability alter the expected response to and toxicities of chemotherapy in patients with this condition. Observations: We report a 16-year-old patient with previously undiagnosed Bloom syndrome who presented with metastatic mucinous adenocarcinoma and tolerated palliative chemotherapy, initially with modified FOLFOX and subsequently with FOLFIRI, both at 50% dose reduction, without significant toxicity. Conclusions: Dose modified multiagent chemotherapy was well tolerated in an adolescent patient with Bloom Syndrome and metastatic colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Baca et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: